Request Demo

Last update 04 Nov 2025

Lisinopril

Last update 04 Nov 2025

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

SummaryLisinopril is a type of medication known as an angiotensin-converting enzyme (ACE) inhibitor that is frequently prescribed for the management of hypertension, heart failure, and other cardiovascular conditions. By preventing the conversion of angiotensin I to angiotensin II, a hormone that causes blood vessels to constrict, lisinopril helps to reduce blood pressure. The medication is available in oral formulations and generally well-tolerated by patients. Nonetheless, side effects, such as cough, dizziness, and hypotension, may occur. As a researcher, it is noteworthy that ongoing investigations into the potential benefits of lisinopril for the treatment of conditions like diabetic nephropathy and migraines have shown encouraging results in preclinical and clinical studies.

Drug Type

Small molecule drug

Synonyms

(S)-1-(N(2)-(1-Carboxy-3-phenylpropyl)-L-lysyl)-L-proline, [N2-[(S)-1-carboxy-3-phenylpropyl]-L-lysyl-L-proline, Lisinopril (INN)

+ [26]

Target

ACE

Action

inhibitors

Mechanism

ACE inhibitors(Angiotensin-converting enzyme inhibitors)

Therapeutic Areas

Cardiovascular DiseasesEndocrinology and Metabolic DiseaseUrogenital Diseases

Active Indication

Diabetic NephropathiesChronic heart failureEssential Hypertension+ [4]

Inactive Indication

Polycystic Kidney, Autosomal Dominant

Originator Organization

Merck Sharp & Dohme Corp.

AstraZeneca PLC

Active Organization

ratiopharm GmbHAstraZeneca KK

TWi Pharmaceuticals, Inc.

+ [6]

Inactive Organization

Alvogen, Inc.

Merck Research Laboratories Massachusetts LLC

License Organization

Moksha8 Pharmaceuticals, Inc.

ATNAHS PHARMA UK LIMITED

AstraZeneca PLC

Drug Highest PhaseApproved

First Approval Date

United States (29 Dec 1987),

Acute myocardial infarctionHeart FailureHypertension

Regulation-

Structure/Sequence

Molecular FormulaC21H35N3O7

InChIKeyCZRQXSDBMCMPNJ-ZUIPZQNBSA-N

CAS Registry83915-83-7

122

Clinical Trials associated with Lisinopril

NCT06745726

/ Not yet recruitingNot Applicable

Optimising Hypertension Management: Real-World Effectiveness of Zestril Personalised Dosing With the OptiZ Software as a Medical Device Companion App

Hypertension, or high blood pressure, is a major cause of preventable illness and premature death, affecting millions in the UK. Despite effective treatments, many patients struggle to achieve adequate blood pressure control. This study evaluates the effectiveness of the OptiZ. OptiZ is a mobile phone application ("app") intended to be installed on a mobile device as part of a treatment for hypertension for use by patients prescribed Zestril (lisinopril). The OptiZ app helps patients record blood pressure, dose-related side effects, and medication adherence, send reports to healthcare professionals for dose adjustments, set reminders to log their medication and blood pressure readings, and access information about high blood pressure and health tips.
This is a real-world observational study involving adults diagnosed with essential hypertension who are eligible for Zestril treatment. Recruitment will occur at selected GP practices across England over six months, with participants followed for 12 months. The study aims to enrol 113 participants. Using the OptiZ app, participants will record daily blood pressure readings, track medication adherence, record dose-related side effects, and access educational content on hypertension management. Healthcare professionals will use reports generated by the app to personalise Zestril dosing.
The main objective is to evaluate the OptiZ app's impact on reducing systolic blood pressure during the dose adjustment phase. Secondary objectives include adherence to Zestril, how often patients log blood pressure readings onto the OptiZ app and other patient-reported outcomes. Participants will also complete electronic questionnaires to provide feedback on their experience using the OptiZ app and their perceptions of hypertension treatment.
This study is funded by Closed Loop Medicine Ltd and Atnahs Pharma UK Ltd. The findings aim to improve hypertension care by using digital tools to enhance adherence, optimise dosing, and potentially reduce cardiovascular risks while guiding future digital solutions for chronic conditions.

Start Date01 Mar 2025

Sponsor / Collaborator

Closed Loop Medicine Ltd.

NCT06372470

/ CompletedNot Applicable

Personalised Dose Optimisation of Zestril Supported by the Digital Blood Pressure Diary in a Primary Care Environment in England: Pragmatic Observational Pilot Study for Remote Hypertension Treatment

A pragmatic observational proof-of-concept study which aims to determine the feasibility of a remote titration clinic, assisted by home blood pressure monitoring and digital solutions, and assess its impact on real-world outcomes. By incorporating home blood pressure monitoring, the study seeks to offer a promising solution for personalised drug titration and self-management, potentially enhancing patient outcomes while optimising Zestril utilisation

Start Date15 Apr 2024

Sponsor / Collaborator

Closed Loop Medicine Ltd.

[+1]

NCT06772779

/ CompletedPhase 1

A Clinical Study to Evaluate the Effect of MK-0616 on Warfarin and Lisinopril Pharmacokinetics in Healthy Adult Participants

The main goal of this study is to learn what happens in a person's body over time when they take enlicitide decanoate with warfarin or lisinopril. Researchers want to learn if the amount of warfarin in a person's blood is similar when warfarin is taken alone or with enlicitide decanoate.
Enlicitide decanoate is a new medicine that lowers the amount of cholesterol in a person's blood. Warfarin is a drug that reduces risk of blood clotting, and lisinopril is a drug that lowers blood pressure.

Start Date01 Apr 2024

Sponsor / Collaborator

Merck Sharp & Dohme LLC

100 Clinical Results associated with Lisinopril

100 Translational Medicine associated with Lisinopril

100 Patents (Medical) associated with Lisinopril

4,314

Literatures (Medical) associated with Lisinopril

01 Dec 2025·Current Cardiology Reports

Blood Pressure Control and Incident Left-Ventricular Conduction Disease

Review

Author: Frimodt-Møller, Emilie K ; Marcus, Gregory M

PURPOSE OF REVIEW:

Cardiac conduction disease, a harbinger of pacemaker implantation, heart failure, and death, is commonly regarded as immutable. However, emerging research suggests it may be a target for upstream prevention strategies such as blood pressure management. This review summarizes recent evidence regarding blood pressure control and the development of conduction disease.

RECENT FINDINGS:

Recent observational studies link hypertension to both prevalent and incident conduction disease. In randomized trials, intensive blood pressure control among hypertensive individuals reduced the incidence of left-ventricular conduction abnormalities in the form of fascicular- and left bundle branch blocks, while treatment with lisinopril independent of blood pressure control appeared to reduce conduction disease risk. Understanding factors that influence conduction system disease development may help inform novel primary prevention strategies. Recent evidence suggests that treatment of hypertension may play a key role in the prevention of conduction disease.

01 Nov 2025·NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY

Exploring the drug repurposing potential of lisinopril against TNBS-induced colitis in Wistar rats

Article

Author: Roy, Supriya ; Sinha, Akshit

Inflammatory bowel disease (IBD) is a chronic inflammatory condition of the gastrointestinal tract with a multifactorial etiology. Given the limitations and adverse effects of current therapies, there is a need for novel therapeutic approaches. Drug repurposing presents a promising opportunity to utilize medications with known safety and pharmacological profiles for alternative colitis treatment. Emerging evidence suggests the renin-angiotensin system (RAS) plays a significant role in the colitis pathophysiology. Angiotensin-converting enzyme (ACE) inhibitors may offer therapeutic potential by modulating pro-inflammatory cytokines and reducing oxidative stress. This study aims to evaluate the efficacy of lisinopril (LIS) in a 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced colitis model in Wistar rats. Colitis was induced in Wistar rats via a single intracolonic TNBS dose (100 mg/kg). Treatment groups received oral interventions for 5 days: 5-aminosalicylic acid (5-ASA; 25.5 mg/kg), LIS (10 mg/kg), or LIS (20 mg/kg). Efficacy was evaluated using the disease activity score rate (DASR), colon/body weight ratio (CBWR), and colon length, diameter, and pH. Colonic tissue was analyzed macroscopically and histopathologically. Inflammatory biomarkers interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), oxidative stress markers glutathione (GSH), and malondialdehyde (MDA), as well as C-reactive protein (CRP) and complete blood count (CBC), were measured. LIS significantly reduced colitis severity, decreasing DASR and CBWR, while restoring colon dimensions and pH. LIS showed potent anti-colitic effects by suppressing TNF-α and IL-6 levels, reducing MDA, and increasing GSH. LIS restored RBC and WBC levels while normalizing CRP and hemoglobin levels. Histopathological and macroscopic analyses confirmed colonic protection with minimal detrimental effects on the stomach and liver. LIS, particularly at 20 mg/kg, exhibited dose-dependent anti-inflammatory, antioxidant, and tissue-protective effects, showing promise as a therapeutic agent for colitis treatment.

20 Sep 2025·Cureus Journal of Medical Science

A Rare Case of Concomitant Fibrillary Glomerulonephritis and Membranous Nephropathy in a Patient With Chronic Inflammatory Demyelinating Polyneuropathy

Article

Author: Hongalgi, Krishnakumar ; Shahzad, Sheikh Raza ; Mehta, Swati ; Foulke, Llewellyn ; Hamza, Mohammad

Fibrillary glomerulonephritis (FGN) is a rare glomerular disorder characterized by non-branching fibrillary deposits visible on electron microscopy (EM). Rarely, FGN may present with light microscopy (LM) features resembling membranous nephropathy (MN). Immunofluorescence (IF) and EM can distinguish the two entities. We describe, to our knowledge, the first reported case of dual FGN and MN in association with chronic inflammatory demyelinating polyneuropathy (CIDP). A 68-year-old woman presented with nephrotic syndrome and CIDP. LM demonstrated diffuse mild mesangial expansion. EM revealed mild glomerular basement membrane thickening, subepithelial granular deposits, and diffuse (>90%) podocyte foot process effacement. Additional mesangial and paramesangial intramembranous fibrillary deposits (12-28 nm diameter) were identified. IF demonstrated diffuse granular capillary and mesangial staining for IgG (3+), C3 (2+), IgA (1+), C1q (trace), kappa (4+), and lambda (4+). M-type phospholipase A2 receptor (PLA2R) staining was strongly positive (3+) with a predominantly subepithelial pattern. The patient was treated with furosemide, lisinopril, prednisone, and tacrolimus, resulting in improved proteinuria and edema. She also received intravenous immunoglobulin for CIDP. FGN may rarely have subepithelial immune deposits resembling MN, but strong anti-PLA2R positivity is unusual and supports the coexistence of two distinct glomerulopathies. The concurrent CIDP raises the possibility of shared immune dysregulation contributing to both renal and neurologic disease. Recognition of such dual pathology is essential, as management may require addressing each condition individually. This case highlights the rare coexistence of FGN and PLA2R-positive MN in a patient with CIDP. Accurate diagnosis requires careful correlation of LM, IF, and EM findings. Further research is warranted to clarify the pathogenesis, clinical implications, and optimal management of dual glomerulopathies.

News (Medical) associated with Lisinopril

24 Jul 2025

·pharma.economictimes.indiatimes.com

Lupin's US arm orders recall of over 58k bottles of hypertension drug

New Delhi: Generics drugmaker Lupin Limited US-arm Lupin Pharmaceuticals is recalling over 58000 bottles of ‘ Lisinopril and Hydrochlorothiazide ’ tablets due to a ‘product Mix Up issue’. According to the USFDA latest enforcement report the company has ordered a voluntary recall of 58,968 bottles of Lisinopril and Hydrochlorothiazide manufactured at the company Nagpur-based facility in India. “This product is being recalled because of a complaint received that a sealed bottle of lisinopril and hydrochlorothiazide tablets 20mg/12.5 mg had a foreign tablet identified as Atazanavir and Ritonavir tablet 300mg/100mg,” the report noted. The ongoing voluntary action is classified as a Class II recall, initiated by the company on June 20, 2025. According to the FDA, a Class II recall is a situation where the probability of serious adverse health consequences is remote and use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences. Lupin’s Lisinopril and Hydrochlorothiazide tablet is a Fixed-Dose Combination (FDC) of Lisinopril and Hydrochlorothiazide, indicated for the treatment of high blood pressure (hypertension). The drug inhibits angiotensin-converting enzyme (ACE) that helps relax blood vessels by blocking the formation of angiotensin II–a chemical that causes blood vessels to constrict–and its Hydrochlorothiazide ingredient is a thiazide diuretic that helps decrease blood volume by removing excess salt and water through the urine, thereby helping to reduce blood pressure. Lisinopril and Hydrochlorothiazide, is a popular hypertension medication marketed under both generic and branded by several drugmakers. By Online Bureau ,

14 Jun 2024

·www.globenewswire.com

Chiesi Global Rare Diseases Showcases Ongoing Commitment to Multiple Rare Diseases Communities at ENDO 2024 Meeting Debut

• Results presented from a large, pooled database from three Phase 3 clinical trials evaluating MYCAPSSA (octreotide) for the treatment of people living with acromegaly • Additional presentations provide insights into the validation of the Lipodystrophy Severity Scoring tool and the Chiesi Management of Acromegaly (MACRO) registry BOSTON, June 14, 2024 (GLOBE NEWSWIRE) -- Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people living with rare diseases, announced updates from their rare endocrine disease portfolio with two late-breaking poster presentations and one oral presentation during the Endocrine Society’s ENDO 2024 Meeting that was held June 1-4, 2024, in Boston, Massachusetts. Presentations included a post hoc analysis of three Phase 3 clinical trials (CH-ACM-01, OPTIMAL, MPOWERED) studying MYCAPSSA (octreotide) as well as real-world MYCAPSSA use data from the Chiesi Management of Acromegaly (MACRO) registry and presentation of the Lipodystrophy Severity Scoring tool designed to assess the disease burden of lipodystrophy. "We're thrilled to support this community of people living with burdensome rare endocrine diseases through the innovation of new resources and validated medicines to aid in disease management," said Giacomo Chiesi, Head of Chiesi Global Rare Diseases. "As we approach the four-year anniversary of MYCAPSSA being on the market later this month, our commitment remains steadfast to commercializing solutions for the acromegaly and lipodystrophy patient communities.” Oral PresentationTitle: Biochemical Response, Symptom Control, and Safety of Oral Octreotide Capsules Treatment in Acromegaly: A Post Hoc Analysis of a Large Pooled Database from Three Phase 3 Clinical Trials2Key Highlights: MYCAPSSA demonstrated a 72% response rate in patients entering the studies with IGF-I values of ≤ 1x the upper limit of normal. A patient’s prior dose level of injectable medication did not significantly impact response rates.In this post-hoc analysis, symptom improvement was notable with significant reductions in joint pain (36% to 22%) and swelling (15% to 10%) in patients responding to MYCAPSSA. Median decrease of one symptom per patient and a mean decrease of 0.8 in Acromegaly Index of Severity (AIS) further underscored symptom improvement.Safety analysis revealed gastrointestinal issues as the most common adverse events with a median duration and time to onset of roughly two weeks for the first occurrence and a low rate of discontinuation. Late-Breaker Poster PresentationsTitle: Real-world Biochemical And Symptoms Outcomes With Oral Octreotide: Management Of Acromegaly (MACRO) Registry Experience3Key Highlights: Of the 230 patients participating in Chiesi Management of Acromegaly (MACRO) registry, 32 (14%) received MYCAPSSA at baseline, with an additional 26 (11%) initiating post-baseline. Common reasons for initiation included patient preference and lack of symptom or biochemical control.The mean time on OOC was 19.7 months, with the majority receiving treatment for at least 6 months. Most patients remained well-controlled biochemically and symptomatically, with 87% biochemically controlled and 71% symptomatically controlled at the last follow-up.The discontinuation rate was 33% and in cases attributed to a lack of biochemical or symptom control, dose titration to 80mg/day was not implemented in many cases.Overall, OOC demonstrated efficacy in maintaining or achieving biochemical control with the majority of newly-initiated patients reporting well-controlled symptoms. Title: Lipodystrophy Severity Score: Validation Of A Tool To Assess Disease Burden In Lipodystrophy4Key Highlights: The lipodystrophy severity score (LDS) is a validated tool that captures severity in patients with diverse manifestations of lipodystrophy. The LDS allows comparisons among patient groups and changes within patients over time.The LDS is a tool designed to quantify the diverse complications of lipodystrophy, a group of rare, potentially life-threatening disorders that affect how the body accumulates and stores fat.The LDSs showed high reliability and strong correlation with the Clinical Global Impression (CGI) of severity, effectively capturing the severity of lipodystrophy and changes over time. This tool is intended to compare patient groups, and monitor individual progress with future analysis involving in real-world data sets.Development into an online platform enhances functionality – a versatile and valuable resource for the lipodystrophy community.Future work will assess the LDS using real-world datasets. MYCAPSSA IMPORTANT SAFETY INFORAMATION INDICATION AND USAGE MYCAPSSA (octreotide) delayed-release capsules, for oral use, is a somatostatin analog indicated for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. CONTRAINDICATIONS Hypersensitivity to octreotide or any of the components of MYCAPSSA. Anaphylactoid reactions, including anaphylactic shock, have been reported in patients receiving octreotide. IMPORTANT SAFETY INFORMATION WARNINGS AND PRECAUTIONS MYCAPSSA can cause problems with the gallbladder. Monitor patients periodically. Discontinue if complications of cholelithiasis are suspected. Blood sugar, thyroid levels, and vitamin B12 levels should be monitored and treated accordingly. Bradycardia, arrhythmia, or conduction abnormalities may occur. Treatment with drugs that have bradycardia effects may need to be adjusted. ADVERSE REACTIONS The most common adverse reactions (incidence >10%) are nausea, diarrhea, headache, arthralgia, asthenia, hyperhidrosis, peripheral swelling, blood glucose increased, vomiting, abdominal discomfort, dyspepsia, sinusitis, and osteoarthritis. DRUG INTERACTIONS The following drugs require monitoring and possible dose adjustment when used with MYCAPSSA: cyclosporine, insulin, antidiabetic drugs, calcium channel blockers, beta blockers, lisinopril, digoxin, bromocriptine, and drugs mainly metabolized by CYP3A4. Counsel women taking an oral contraceptive to use an alternative non-hormonal method of contraception or a back-up method when taking MYCAPSSA. Patients taking proton pump inhibitors, H2-receptor antagonists, or antacids concomitantly with MYCAPSSA may require increased dosages of MYCAPSSA. PREGNANCY Advise premenopausal females of the potential for an unintended pregnancy. Please contact Chiesi Farmaceutici S.p.A. at 1-888-661-9260 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. About AcromegalyAcromegaly typically develops when a benign tumor of the pituitary gland produces too much growth hormone, ultimately leading to significant health problems. Common features of acromegaly are facial changes, intense headaches, joint pain, impaired vision, and enlargement of the hands, feet, tongue, and internal organs. Serious health conditions associated with the progression of acromegaly include type 2 diabetes, hypertension, respiratory disorders, and cardiac and cerebrovascular disease. Acromegaly affects over 25,000 people in the United States alone with roughly 8,000 being treated with injectable somatostatin receptor ligands (iSRLs). A significant percentage of these people experience burdens associated with receiving iSRLs including prolonged injection-related pain and poorly-controlled symptoms. About LipodystrophyLipodystrophy syndromes are a heterogeneous group of rare, potentially life-threatening disorders that affect how the body accumulates and stores fat. These syndromes are categorized into two main forms: generalized lipodystrophy, characterized by the near-complete absence or progressive loss of fat (adipose) tissue, and partial lipodystrophy, where the tissue loss is more limited, typically impacting areas like limbs or upper body. Lipodystrophy is also categorized by etiology with inherited and acquired forms1. About Chiesi Global Rare DiseasesChiesi Global Rare Diseases is a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people affected by rare diseases. As a family business, Chiesi Group strives to create a world where it is common to have a therapy for all diseases and acts as a force for good, for society and the planet. The goal of the Global Rare Diseases unit is to ensure equal access so as many people as possible can experience their most fulfilling life. The unit collaborates with the rare disease community around the globe to bring voice to underserved people in the health care system. For more information visit www.chiesirarediseases.com. About Chiesi GroupChiesi is an international, research-focused biopharmaceuticals group that develops and markets innovative therapeutic solutions in respiratory health, rare diseases, and specialty care. The company’s mission is to improve people’s quality of life and act responsibly towards both the community and the environment. By changing its legal status to a Benefit Corporation in Italy, the US, and France, Chiesi’s commitment to create shared value for society as a whole is legally binding and central to company-wide decision-making. As a certified B Corp since 2019, we’re part of a global community of businesses that meet high standards of social and environmental impact. The company aims to reach Net-Zero greenhouse gases (GHG) emissions by 2035. With over 85 years of experience, Chiesi is headquartered in Parma (Italy), operates in 31 countries, and counts more than 6,500 employees. The Group’s research and development centre in Parma works alongside 6 other important R&D hubs in France, the US, Canada, China, the UK, and Sweden. For further information please visit www.chiesi.com Garg A. Acquired and inherited lipodystrophies. N Engl J Med. 2004 Mar 18;350(12):1220-34. Doi: 10.1056/NEJMra025261. PMID: 15028826.Fleseriu M, et al. Biochemical Response, Symptom Control, and Safety of Oral Octreotide Capsules Treatment in Acromegaly: A Post Hoc Analysis of a Large Pooled Database from Three Phase 3 Clinical Trials. Presented at: Endocrine Society’s ENDO 2024 Meeting; June 1-4, 2024; Boston, Massachusetts.Yuen K, et al. Real-world Biochemical And Symptoms Outcomes With Oral Octreotide: Management Of Acromegaly (MACRO) Registry Experience. Presented at: Endocrine Society’s ENDO 2024 Meeting; June 1-4, 2024; Boston, Massachusetts.Brown R, et al. Lipodystrophy Severity Score: Validation Of A Tool To Assess Disease Burden In Lipodystrophy. Presented at: Endocrine Society’s ENDO 2024 Meeting; June 1-4, 2024; Boston, Massachusetts. Chiesi Group Media ContactChiara TravaginRare Communication ManagerTel: +39 348 8818985Email c.travagin@chiesi.com Sky Striar LifeSci CommunicationsTel: 617-797-6672Email sstriar@lifescicomms.com

Clinical ResultPhase 3

06 Jun 2024

·www.drugs.com

Several Drugs Linked to Risk for Aneurysmal Subarachnoid Hemorrhage

THURSDAY, June 6, 2024 -- Several commonly prescribed drugs are associated with aneurysmal subarachnoid hemorrhage (aSAH), according to a study published online June 5 in Neurology . Jos P. Kanning, from the University Medical Center Utrecht in the Netherlands, and colleagues conducted a drug-wide association study to examine the association between commonly prescribed drugs and aSAH incidence. Use of commonly prescribed drugs was examined across exposure windows (current, within three months; recent, three to 12 months; and past, >12 months). Exposure to 205 commonly prescribed drugs was investigated among 4,879 aSAH cases and 43,911 matched controls. The researchers found similar trends for lisinopril and amlodipine, with a decreased risk for aSAH in association with current use, while the risk for aSAH was increased with recent use. The risk for aSAH was reduced with current use of simvastatin, metformin, and tamsulosin. Increased aSAH risk was seen in association with current use of warfarin, venlafaxine, prochlorperazine, and co-codamol. "Future research should use a more hypothesis-driven approach to further investigate these associations and differentiate between drug class and specific drug substance effects," the authors write. "In addition, this research may help identify additional risk factors for aSAH, potentially leading to new pharmacologic therapy options for aneurysmal management." Abstract/Full Text Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

Clinical ResultClinical Study

100 Deals associated with Lisinopril

External Link

KEGG	Wiki	ATC	Drug Bank
D08131	Lisinopril	C09AA03	DB00722

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Diabetic Nephropathies	Austria	ratiopharm GmbH	18 Feb 2001
Diabetic Nephropathies	Finland	ratiopharm GmbH	18 Feb 2001
Diabetic Nephropathies	Germany	ratiopharm GmbH	18 Feb 2001
Diabetic Nephropathies	Italy	ratiopharm GmbH	18 Feb 2001
Diabetic Nephropathies	Luxembourg	ratiopharm GmbH	18 Feb 2001
Diabetic Nephropathies	Norway	ratiopharm GmbH	18 Feb 2001
Diabetic Nephropathies	Portugal	ratiopharm GmbH	18 Feb 2001
Diabetic Nephropathies	Spain	ratiopharm GmbH	18 Feb 2001
Chronic heart failure	Japan	Kyowa Pharmaceutical Industry Co., Ltd.	30 Jun 1995
Essential Hypertension	Switzerland	ATNAHS PHARMA UK LTD	08 May 1989
Hypertension, Renovascular	Switzerland	ATNAHS PHARMA UK LTD	08 May 1989
Acute myocardial infarction	United States	Merck Research Laboratories Massachusetts LLC	29 Dec 1987
Heart Failure	United States	Merck Research Laboratories Massachusetts LLC	29 Dec 1987
Hypertension	United States	Merck Research Laboratories Massachusetts LLC	29 Dec 1987

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Polycystic Kidney, Autosomal Dominant	Phase 3	United States	Alvogen, Inc.	09 Jan 2015

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT00430040 (CTgov)	Phase 4	Diabetes Mellitus, Type 2 \| Inflammation \| Hypertension ... View more	14	lisinopril+Carvedilol (Carvedilol)	lrryvmpuji(vaikayguor) = fyomrwanpg islgvwrcfx (nedqenfuuo, 20) View more	-	16 Apr 2024
				lisinopril (Lisinopril)	lrryvmpuji(vaikayguor) = pqqgcdpxog islgvwrcfx (nedqenfuuo, 17) View more
NCT02184858 (SAFEPEDRUG project, Pubmed \| Br J Clin Pharmacol)	Phase 4	Hypertension estimated glomerular filtration rate (eGFR)	13	Lisinopril	tawnrvcssw(mwswvreiuw) = kyqbebspyt vyhwnwcmtw (hkoeervayi, 0.062 - 0.088) View more	Positive	01 Feb 2024
NCT03461003 (NICHE, CTgov)	Phase 4	Hypertension	49	NICHE method+Lisinopril+Hydrochlorothiazide+Amlodipine+Losartan (NICHE Method)	iakaazahan(hwpwtwndut) = heliqsqyyq jfobmwndon (dxdvowljrk, 9.301) View more	-	09 Sep 2022
				Usual care (Usual Care)	iakaazahan(hwpwtwndut) = vlqsawyjzs jfobmwndon (dxdvowljrk, 9.586) View more
NCT01009918 (Lisinopril or Coreg CR in Reducing Side Effects in Women With Breast Cancer Receiving Trastuzumab, CTgov)	Phase 2	Cardiotoxicity \| Breast Cancer \| HER2 Positive Breast Cancer	468	lisinopril (Arm I Lisinopril)	lqufzxbupa = vnnyvcakok bmicpslcqy (keypphnckx, pxbbezgfef - anivlghidh) View more	-	30 Mar 2021
				Coreg CR® (Arm II Coreg CR®)	lqufzxbupa = ljtcmmdgix bmicpslcqy (keypphnckx, nekyzulotc - wmokhvkomz) View more
NCT01984164 (CALIBREX, CTgov)	Phase 2	Mild cognitive disorder \| Hypertension	176	Candesartan (Candesartan)	aqnjbalwzr(jipjunxwgz) = lvoxnoymnu ncijsgqgpp (jhswciagar, 5.46) View more	-	21 Feb 2021
				Lisinopril (Lisinopril)	aqnjbalwzr(jipjunxwgz) = gckcbprecl ncijsgqgpp (jhswciagar, 5.89) View more
NCT00874432 (CTgov)	Phase 2	Aortic Diseases \| Chronic Kidney Diseases	43	angiotensin converting enzyme inhibitor (Chronic Kidney Disease)	tnjyxkwkfb(lhxliycrwb) = scxwcvbfws ypajqepmob (yjpoxpcohd, 1.12) View more	-	23 Sep 2020
				angiotensin converting enzyme inhibitor (Age Matched Control)	tnjyxkwkfb(lhxliycrwb) = kszhifvbgh ypajqepmob (yjpoxpcohd, 2.52) View more
NCT00673790 (CTgov)	Phase 4	Glucose Intolerance \| Hypertension	537	lisinopril+Nebivolol+losartan (Nebivolol)	xqkgfndzxo(hvfjuvdxeh) = ykkqaplbmv ggoucblrxy (hpmwbkbpsd, 8.9) View more	-	26 Feb 2020
				lisinopril+losartan (Placebo)	xqkgfndzxo(hvfjuvdxeh) = fagmwvmauw ggoucblrxy (hpmwbkbpsd, 9.5) View more
NCT01880528 (CTgov)	Phase 2	Dyspnea \| Small Cell Lung Cancer \| Non-Small Cell Lung Cancer	23	lisinopril (Arm I (Lisinopril))	duvcrktdgy = hnafxobsqe yvsiaiqxzy (mvwbcsekoa, sotyorsdyp - gumnblopig) View more	-	17 Sep 2019
				placebo (Arm II (Placebo))	duvcrktdgy = bkcufzhlxn yvsiaiqxzy (mvwbcsekoa, bigtrrsaep - sggaubvvao) View more
NCT01009918 (Lisinopril or Coreg CR in Reducing Side Effects in Women With Breast Cancer Receiving Trastuzumab, Pubmed \| J Am Coll Cardiol)	Phase 2	Cardiotoxicity \| Breast Cancer	468	Lisinopril	pmozuofxjs(cjjqxuxjhj) = wkcvhslqjw rogakrvjyp (vhojgqsetc )	-	11 Jun 2019
				Carvedilol	pmozuofxjs(cjjqxuxjhj) = oqmbbwrpmk rogakrvjyp (vhojgqsetc )
NCT00000542 (ALLHAT, Pubmed)	Phase 3	Hypertension ECG LVH \| BP	-	chlorthalidone	tqqrvhmezw(rmwgevcozu): HR = 1.78 (95% CI, 1.43 - 2.22)	-	16 Apr 2019
				doxazosin

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis